Orthofix Reports Q3 2026 Results and Revises Full-Year Guidance
Third-quarter sales rose 1.1%, adjusted EBITDA was $26.0 million and the net loss narrowed to $6.1 million. Orthofix cited distributor and supply constraints in Global Spine, offset by growth in Global Limb Reconstruction.
Orthofix Medical Inc. reported its third-quarter 2026 financial results, highlighting a 1.1% increase in sales and an adjusted EBITDA of $26.0 million. The company's net loss narrowed to $6.1 million during the period. Performance was mixed across segments, with strong growth in Global Limb Reconstruction offset by distributor and supply constraints within the Global Spine business.
Additionally, the company announced a revision to its full-year financial guidance. Management continues to monitor cash flow and legal exposure as key considerations for the business.